These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 12615565)
1. Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Holmes C; Lovestone S Age Ageing; 2003 Mar; 32(2):200-4. PubMed ID: 12615565 [TBL] [Abstract][Full Text] [Related]
2. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Morris JC; Edland S; Clark C; Galasko D; Koss E; Mohs R; van Belle G; Fillenbaum G; Heyman A Neurology; 1993 Dec; 43(12):2457-65. PubMed ID: 8255439 [TBL] [Abstract][Full Text] [Related]
4. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy. Modrego PJ; Pina MA; Fayed N; Díaz M CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455 [TBL] [Abstract][Full Text] [Related]
5. Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging. Friedman JI; Harvey PD; Coleman T; Moriarty PJ; Bowie C; Parrella M; White L; Adler D; Davis KL Am J Psychiatry; 2001 Sep; 158(9):1441-8. PubMed ID: 11532729 [TBL] [Abstract][Full Text] [Related]
6. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Stern RG; Mohs RC; Davidson M; Schmeidler J; Silverman J; Kramer-Ginsberg E; Searcey T; Bierer L; Davis KL Am J Psychiatry; 1994 Mar; 151(3):390-6. PubMed ID: 8109647 [TBL] [Abstract][Full Text] [Related]
7. Executive dysfunction in Alzheimer's disease: association with neuropsychiatric symptoms and functional impairment. Chen ST; Sultzer DL; Hinkin CH; Mahler ME; Cummings JL J Neuropsychiatry Clin Neurosci; 1998; 10(4):426-32. PubMed ID: 9813788 [TBL] [Abstract][Full Text] [Related]
8. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H; Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152 [TBL] [Abstract][Full Text] [Related]
9. A neuropsychological test battery for use in Alzheimer disease clinical trials. Harrison J; Minassian SL; Jenkins L; Black RS; Koller M; Grundman M Arch Neurol; 2007 Sep; 64(9):1323-9. PubMed ID: 17846273 [TBL] [Abstract][Full Text] [Related]
10. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. Suh GH; Ju YS; Yeon BK; Shah A Int J Geriatr Psychiatry; 2004 Sep; 19(9):817-24. PubMed ID: 15352138 [TBL] [Abstract][Full Text] [Related]
12. Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Jacobs D; Sano M; Marder K; Bell K; Bylsma F; Lafleche G; Albert M; Brandt J; Stern Y Neurology; 1994 Jul; 44(7):1215-20. PubMed ID: 8035918 [TBL] [Abstract][Full Text] [Related]
13. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Modrego PJ; Ferrández J Arch Neurol; 2004 Aug; 61(8):1290-3. PubMed ID: 15313849 [TBL] [Abstract][Full Text] [Related]
14. Prediction of the rate of decline in cognitive function in Alzheimer's disease: a model based on simple demographic data and widely used rating scales. Johnsen S; Hughes S; Bullock R; Hindmarch I Dement Geriatr Cogn Disord; 2003; 16(4):276-82. PubMed ID: 14512724 [TBL] [Abstract][Full Text] [Related]
15. Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study. Hallikainen I; Hänninen T; Fraunberg M; Hongisto K; Välimäki T; Hiltunen A; Karppi P; Sivenius J; Soininen H; Koivisto AM; Int Psychogeriatr; 2013 Aug; 25(8):1335-44. PubMed ID: 23676340 [TBL] [Abstract][Full Text] [Related]
17. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Raskind MA; Peskind ER; Truyen L; Kershaw P; Damaraju CV Arch Neurol; 2004 Feb; 61(2):252-6. PubMed ID: 14967774 [TBL] [Abstract][Full Text] [Related]
18. The Clock Drawing Test for dementia of the Alzheimer's type: A comparison of three scoring methods in a memory disorders clinic. Brodaty H; Moore CM Int J Geriatr Psychiatry; 1997 Jun; 12(6):619-27. PubMed ID: 9215942 [TBL] [Abstract][Full Text] [Related]
19. Neuropsychological and psychiatric differences between Alzheimer's disease and Parkinson's disease with dementia. Starkstein SE; Sabe L; Petracca G; Chemerinski E; Kuzis G; Merello M; Leiguarda R J Neurol Neurosurg Psychiatry; 1996 Oct; 61(4):381-7. PubMed ID: 8890777 [TBL] [Abstract][Full Text] [Related]